- Takeda leads Asia's acquisitive charge in 2012/13
- INTERVIEW: Lupin head on US plans, fair biosimilar pricing and 'letting go'
- US Capitol Capsule: Rare disease research hopeful, but therapy success remains low
- India to regulate phytopharmaceuticals but experts shy away from US route
ANALYSIS Other Informa Analysis
COMMENT Other Informa Comment
FEATURES Other Informa Features